GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

By providing a complete, timely view of the de-identified patient journey, including more than 5 billion clinical notes, nearly 100 million medical images, and billions ... PhD, et al. Semaglutide vs ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

Scrolling through photos from my husband’s birthday party last year ... There’s been talk of GLP-1 and semaglutide drugs, ...

The new rules, which cover both TV and radio, instruct drugmakers to use simple, consumer-friendly language when describing ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...

Ministers have been urged to ditch "gimmicks and soundbites" while addressing the soaring cost of obesity to the NHS.

Novo and Lilly also market their GLP-1s for weight loss under, respectively, Wegovy (semaglutide) and Zepbound (tirzepatide). "In most countries, especially in low-income and middle-income countries, ...

As a new study finds that people who stopped taking semaglutide, the active ingredient in the new blockbuster weight loss ...